Syncopal episodes associated with cisapride and concurrent drugs

Annals of Pharmacotherapy

Volumn 32, Issue 6, 1998, Pages 648-651

  Gray, Vanessa Seals ^a,b  

^a SAMFORD UNIVERSITY   (United States)

^b HealthSouth Corporation   (United States)

Author keywords

Cisapride; Clarithromycin; QT prolongation

Indexed keywords

ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; ERYTHROMYCIN; ISOENZYME; MACROLIDE; OMEPRAZOLE; PHENOTHIAZINE; PYRROLE; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CASE REPORT; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; ELECTROCARDIOGRAM; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; SYNCOPE;

ACCIDENTS, TRAFFIC; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LONG QT SYNDROME; MIDDLE AGED; OMEPRAZOLE; PIPERIDINES; SYNCOPE;

EID: 0031746252     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17288     Document Type: Article

References (25)

1. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988;36:652-81.
2. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-82.
3. Krikler DM, Perelman M, Rowland E. Ventricular tachycardia and ventricular fibrillation. In: Mandel WJ, ed. Cardiac arrhythmias. Their mechanism, diagnosis and management. Philadelphia: JB Lippincott Co., 1992:517-39.
4. Honig PK. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
5. Package insert. Prozac (fluoxetine). Indianapolis: Eli Lilly and Co., June 1997.
6. Fluoxetine hydrochloride. In: McEvoy GK, ed. American hospital formulary service drug information 1997. Bethesda, MD: American Society of Health-System Pharmacists, 1997:1694-706.
7. Package insert. Catapres (clonidine). Ridgefield. CT: Boehringer Ingelheim Pharmaceuticals, Inc., August 1996.
8. Clonidine hydrochloride. In: McEvoy GK, ed. American hospital formulary service drug information 1997. Bethesda, MD: American Society of Health-System Pharmacists, 1997:1369-74.
9. Package insert. Cisapride (propulsid). Titusville, NJ: Janssen Pharmaceutica, Inc., February 1997.
10. Propulsid. In: McEvoy GK, ed. American hospital formulary service drug information 1997. Bethesda, MD: American Society of Health-System Pharmacists, 1997:2269-72.
11. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high dose cisapride. Arch Intern Med 1995;155:765-8.
12. Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride-induced long QT interval. J Pediatr 1996;128:279-81.
13. Murray M. P450 enzyme inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-46.
14. von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995;13:105-22.
15. Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993;71:1002-9.
16. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32:1-21.
17. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53: 401-9.
18. Flockhart DA. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet 1995;29:45-52.
19. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP 2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996;24: 1081-7.
20. Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. J Biol Med 1996;69:203-9.
21. Tybring G, Bottiger Y, Widen J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP 2C19 in Swedish white subjects. Clin Pharmacol Ther 1997;62:129-37.
22. Caraco Y, Wilkinson GR, Wood AJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996;60:396-404.
23. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia (letter). N Engl J Med 1996;335:290-1.
24. Metz DC, Getz HD. Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. Dig Dis Sci 1995;40:912-5.
25. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, Debartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995;39:2078-83.